You have to wander around a bit. From the AGPH home page click on
Investor Relations, then on Information Fact Sheet. From the AGPH
Fact Sheet...
<<<<<<<<<<
Non-nucleoside Reverse Transcriptase Inhibitor
Developing new compounds that improve upon the efficacy, safety and resistance profiles of currently availableagents is an importantt goal in the evolving treatment of HIV infection. Agouron will develop and commercialize a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. Discovered by shionogi & Co., Lte., Osaka, Japan, this compound (AG1549) is currently the subject of several clinical trials evaluating its dose and its concomitant use with other antiretroviral treatments. Agouron will move swiftly to initiate additional clinical
trials to further evaluate its utility in the treatment of HIV.
>>>>>>>>>>
<<<<<<<<<<
PRODUCT PIPELINE
NAME ENZYME TARGET
AG1661 HIV-1 Immunogen Clin: PIII
AG3340 Matrix metalloprotease (MMP) inhibitor for cancer Clin: PIII
AG1549 Non-nucleoside reverse transcriptase inhibitor Clin: PII
AG3340 Matrix metalloprotease inhibitor for ophthalmic
disease (acute macular degeneration) Clin: PII
AG2037 GART inhibitor backup Preclinical
AG7088 Rhinovirus 3C protease inhibitor for respiratory Preclinical
infections (common cold)
AG1776 HIV protease inhibitor Preclinical
MMP third generation Preclinical
PARP enzyme inhibitors for cancer Research
cdk4/cdk2 inhibitors for cancer Research
Hepatitis C protease inhibitors Research
VEGF receptor for cancer and ophthalmic disease Research
GnRH antagonist for cancer Research
HIV integrase inhibitors Research
>>>>>>>>
(Sorry for the table formatting)
They also have a Research page with brief summaries of work in
that area. From their Research page,
<<<<<<<<<<<<
HIV Integrase for HIV Infection
Development Status:
Research
HIV integrase is one of three viral-encoded enzymes required for replication of HIV inside a host cell (the two other enzymes are reverse transcriptase and protease). The life cycle of HIV begins when HIV attaches itself to the membrane of the target host cell,
enters the cytoplasm of the cell, and then reverse-transcribes itself into viral copy DNA (cDNA) using reverse transcriptase. Integrase then integrates, or inserts, the viral cDNA into the chromosomal DNA of the infected host cell. Only when integration is complete is
the proviral HIV DNA then able to direct the production of new viral proteins and the assembly of these viral proteins into new viral particles. Integration is therefore a critical step in the completion of the viral life cycle and subsequent production of new viral
particles.
Agouron scientists believe that blocking HIV integrase is a viable therapeutic strategy that will abort completion of the viral life cycle, preventing infection of new, uninfected target cells. Scientists also believe that HIV integrase is an attractive target, because it is extremely unlikely an HIV integrase-specific inhibitor will nonspecifically inhibit other eukaryotic enzymes. This fact may possibly reduce the incidence of side effects of an integrase inhibitor used to treat HIV infection.
>>>>>>>>>>>> |
